Mentions
Extended reach
Total likes
Video views
AI synopsis
Throughout the discussions, commenters reference the research's detailed findings, such as rapid symptom improvement within 24 hours, and emphasize the significance of a large-scale trial involving over 200 participants. The tone indicates that many see this as a promising development in depression treatment, with words like 'support,' 'favorable improvement,' and 'clinically relevant' conveying both respect and excitement about the findings.
Most discussions acknowledge and support the findings of the publication, highlighting its positive results and potential clinical value.
Posts demonstrate high curiosity, referencing specific details like rapid improvement and large scope, indicating strong relevance and engagement with the research.
Several posts cite data, mention the study size, and discuss implications for treatment, showing thoughtful engagement rather than superficial reactions.
Discussions emphasize the significance of an emerging treatment for resistant depression and the importance of safety and efficacy data, suggesting perceived high impact on clinical practice and future research.
هنا نص التجربة و التي بعدها تمت الموافقة على الدواء، النص نُشر حديثا التجربة تمت في ٥ دول، الملفت سرعة الاستجابة (و أيضا سرعة الانتكاس) للدواء، بعد ٢٨ يوم الاختلاف واضح بين المجموعتين (لكنه غير مثير بالرغم من انه قياسي بتاريخ تجارب مضادات الاكتئاب) النص https://t.co/4KPVYcaCx8
4. Maybe do some research about ketamine use in treatment-resistant depression instead of cracking ableist jokes about the use of “horse tranquilizers” for depressed people? It's new, but not fringe. https://t.co/sCjhGO7roX https://t.co/kHhAEA3mdC
This year our Impact Factor rose above 19, which ranks AJP among the highest in the top 200 of all indexed journals, ahead of 99% of the rest of the publishing world. Here is our most cited article in the reporting period. https://t.co/eB3YfHND4e https://t.co/dhAlo5G1cN
@eturnermd1 @NaudetFlorian @jppharm @brendon_watson AJP paper: https://t.co/fMWytxI4xg Now for the two negative trials to be published.
Esketamine nasal spray (56 or 84 mg twice weekly) + new antidepressant (NAD) reduces MADRS score greater and quickly than NAD + placebo at day 28 (difference of LSM=−4.0; −7.31 to −0.64) https://t.co/RoVt8sExk9
more Janssen-funded research showing safety and efficacy of esketamine to treat treatment-resistant depression, but despite FDA approval we still don't know what safe and effective dose would make effect last. https://t.co/qTqndCYI1h
Discover the potential of esketamine in treating resistant depression. This video explains its benefits, effectiveness, and unique action mechanism, offering hope for those who have not responded to traditional…
Intranasal Esketamine shows utility in two clinical scenarios: treatment-resistant depression and acute suicidal ideation. Patients who have not responded to multiple treatment strategies may benefit from Spravato…
This video explores the development of esketamine as a nasal spray approved in 2019 for treatment-resistant depression, covering molecular properties, animal models, clinical trials, and the FDA approval process.
4. Maybe do some research about ketamine use in treatment-resistant depression instead of cracking ableist jokes about the use of “horse tranquilizers” for depressed people? It's new, but not fringe. https://t.co/sCjhGO7roX https://t.co/kHhAEA3mdC
RT @APAPubJournals: This year our Impact Factor rose above 19, which ranks AJP among the highest in the top 200 of all indexed journals, ah…
This year our Impact Factor rose above 19, which ranks AJP among the highest in the top 200 of all indexed journals, ahead of 99% of the rest of the publishing world. Here is our most cited article in the reporting period. https://t.co/eB3YfHND4e https://t.co/dhAlo5G1cN
RT @ForensicMHSA: Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treat…
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. https://t.co/U7GLxVRj57
RT @Nouraobaid4: https://t.co/f1w2MyIDcj
https://t.co/f1w2MyIDcj
@JuddLegum Here's a link to the abstract of a recently published study. Buyer beware.... https://t.co/FeWobvjsVy
Trump says he's buying lots of a newly approved drug for veterans with #treatment-resistantdepression. This recent study used another antidepressant along with the nasal spray. Only 198 subjects... Buyer beware. https://t.co/FeWobvjsVy
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry https://t.co/7La86B8L3y
Esketamine in depression data published - https://t.co/hKpwLZHCca Great to have a new antidepressant treatment emerging but we really need long term safety data
治療抵抗性うつ病に対してエスケタミン点鼻はMADRS（うつ病評価尺度）を有意に改善させた。観察機関28日。 Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression:... https://t.co/OON4B4ddfj
RT @Psychiatry_DDx: هنا نص التجربة و التي بعدها تمت الموافقة على الدواء، النص نُشر حديثا التجربة تمت في ٥ دول، الملفت سرعة الاستجابة (و أي…
@eturnermd1 @NaudetFlorian @jppharm @brendon_watson AJP paper: https://t.co/fMWytxI4xg Now for the two negative trials to be published.
Esketamine nasal spray (56 or 84 mg twice weekly) + new antidepressant (NAD) reduces MADRS score greater and quickly than NAD + placebo at day 28 (difference of LSM=−4.0; −7.31 to −0.64) https://t.co/RoVt8sExk9
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry https://t.co/7ej3xjIAhu
Esketamine + antidepressant better than antidepressant + placebo at day 28 in TRD (LSM=−4.0, SE=1.69, 95% CI=−7.31, −0.64); likewise, improvement was observed in the EKT+AD arm at earlier time points. Adverse events resolved by 1.5 hours after dosing https://t.co/RoVt8sExk9
هنا نص التجربة و التي بعدها تمت الموافقة على الدواء، النص نُشر حديثا التجربة تمت في ٥ دول، الملفت سرعة الاستجابة (و أيضا سرعة الانتكاس) للدواء، بعد ٢٨ يوم الاختلاف واضح بين المجموعتين (لكنه غير مثير بالرغم من انه قياسي بتاريخ تجارب مضادات الاكتئاب) النص https://t.co/4KPVYcaCx8
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry https://t.co/dghb7CcFnX
RT @amp6: more Janssen-funded research showing safety and efficacy of esketamine to treat treatment-resistant depression, but despite FDA a…
more Janssen-funded research showing safety and efficacy of esketamine to treat treatment-resistant depression, but despite FDA approval we still don't know what safe and effective dose would make effect last. https://t.co/qTqndCYI1h
Nasal spray esketamine with evident improvement within the first 24 hours The study was large in scope, including over 200 adults at dozens of outpatient health centers over nearly two years. Individuals... https://t.co/rRqeHxblOR
RT @AmJPsychiatry: New study finds clinically relevant, favorable improvement in symptoms of #depression with #esketamine nasal spray in co…
RT @AmJPsychiatry: New study finds clinically relevant, favorable improvement in symptoms of #depression with #esketamine nasal spray in co…
RT @AmJPsychiatry: New study finds clinically relevant, favorable improvement in symptoms of #depression with #esketamine nasal spray in co…
Este ensayo respalda la eficacia y seguridad del aerosol nasal de esketamina como antidepresivo de acción rápida para pacientes con depresión resistente. https://t.co/tJuUNWKyiU https://t.co/CQeXsX8a8h
RT @AmJPsychiatry: New study finds clinically relevant, favorable improvement in symptoms of #depression with #esketamine nasal spray in co…